IP Verse

Dry Powder Formulation Comprising An Anticholinergic, A Corticosteroid And A Beta-Adrenergic For Administration By Inhalation - EP3019153

The patent EP3019153 was granted to Chiesi Farmaceutici on Sep 5, 2018. The application was originally filed on Jul 10, 2014 under application number EP14747855A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3019153

CHIESI FARMACEUTICI
Application Number
EP14747855A
Filing Date
Jul 10, 2014
Status
Granted And Under Opposition
Aug 3, 2018
Grant Date
Sep 5, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSJun 5, 2019ELKINGTON AND FIFEWITHDRAWN

Patent Citations (17) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP20130165483-
DESCRIPTIONEP1760008
DESCRIPTIONWO0178693
DESCRIPTIONWO0178695
DESCRIPTIONWO2004012801
DESCRIPTIONWO2011076841
DESCRIPTIONWO2011076843
DESCRIPTIONWO2011131663
INTERNATIONAL-SEARCH-REPORTUS2004202616
INTERNATIONAL-SEARCH-REPORTUS2007212422
INTERNATIONAL-SEARCH-REPORTUS2011262543
INTERNATIONAL-SEARCH-REPORTWO2011120779
OPPOSITIONUS2004202616
OPPOSITIONUS2007212422
OPPOSITIONUS2011262543
OPPOSITIONWO0178693
OPPOSITIONWO2011120779

Non-Patent Literature (NPL) Citations (6) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- "Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD", Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, (20130000), pages FP - 78, XP055418996-
OPPOSITION- "Meggle sieved, milled and micronized alpha-lactose monyhydrate for dry powder inhalation: InhaLac®", Technical brochure InhaLac®, Wasserburg, Germany, (20180500), pages 1 - 8, XP055628475-
OPPOSITION- N.Y.K. CHEW et al., "Effect of powder polydispersity on aerosol generation", J Pharm Pharmaceut Sci, (20020000), vol. 5, no. 2, pages 162 - 168, XP009056927-
OPPOSITION- X.M. ZENG et al., "5 Particulate interactions in dry powder aerosols", Particulate interactions in dry powder formulations for inhalation, London, (20010000), pages 133 - 138, XP055274532-
OPPOSITION- M. D. JONES et al., "The influence of fine excipient particles on the performance of carrier- based dry powder inhalation formulations", Pharmaceutical Research, (20060000), vol. 23, doi:10.1007/s11095-006-9012-7, pages 1665 - 1674, XP019405166
OPPOSITION- M. KUMON et al., "Novel approach to DPI carrier lactose with mechanofusion process with additives and evaluation by IGC", Chem Pharm Bull, (20060000), vol. 54, doi:10.1248/cpb.54.1508, pages 1508 - 1514, XP055561992

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents